| Description | Avorelin, a luteinizing hormone releasing hormone (LH-RH) agonist, is used potentially for the treatment of prostate. |
| Synonyms | MF-6001, EP 23904, EP-23904, EP23904, MF6001 |
| molecular weight | 1296.48 |
| Molecular formula | C65H85N17O12 |
| CAS | 140703-49-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Kaisary AV, Bowsher WG, Gillatt DA, Anderson JB, Malone PR, Imbimbo BP. Pharmacodynamics of a long acting depot preparation of avorelin in patients with prostate cancer. Avorelin Study Group. J Urol. 1999 Dec;162(6):2019-23. PubMed PMID: 10569560. 2. Brown GR, Dixson AF. Investigation of the role of postnatal testosterone in the expression of sex differences in behavior in infant rhesus macaques (Macaca mulatta). Horm Behav. 1999 Apr;35(2):186-94. PubMed PMID: 10202126. 3. Brown GR, Nevison CM, Fraser HM, Dixson AF. Manipulation of postnatal testosterone levels affects phallic and clitoral development in infant rhesus monkeys. Int J Androl. 1999 Apr;22(2):119-28. PubMed PMID: 10194644. |